Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.31 |
| ▸ | HPGD | P15428 | 5/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15308503 | 0.80 | ALDH1A1 (0.34) | ALDH1A1HPGDSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16629031 | 0.77 | ALDH1A1 (0.33) | ALDH1A1HPGDSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16077836 | 0.73 | PLAT (0.47) | ALDH1A1HPGDKDM4EKMT2APOLB | |
| SCHEMBL21483570 | 0.73 | PLAT (0.36) | — | |
| SCHEMBL15308601 | 0.73 | PLAT (0.47) | ALDH1A1HPGDSMN1; SMN2KDM4ERAB9A | |
| SCHEMBL15225145 | 0.71 | — | — | |
| SCHEMBL5788398 | 0.71 | PLAT (0.34) | ALDH1A1HPGDSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL16535098 | 0.68 | EGLN2 (0.40) | — | |
| SCHEMBL27223068 | 0.68 | POLB (0.34) | KMT2APOLB | |
| SCHEMBL16946611 | 0.65 | PLAT (0.56) | ALDH1A1SMN1; SMN2KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710446-B1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | LILLY CO ELI (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-111344292-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210032257-A1 | (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-20210032257-A1 | (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10787460-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | ELI LILLY AND COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787460-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | ELI LILLY AND COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3710446-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | Eli Lilly and Company (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111344292-A | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10472370-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472370-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190144456-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2019-05-16 | — | — | US | disclosed |
| US-20190144456-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | ELI LILLY AND COMPANY | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144456-A1 | COMPOUNDS USEFUL FOR INHIBITING CDK7 | CDK7, CDK17, CDK8 | ALDH1A1 3836/4885HPGD 2946/4885SMN1; SMN2 1888/4885 |
| US-10472370-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | CDK7, CDK9, CDK8 | ALDH1A1 2171/4885HPGD 3112/4885SMN1; SMN2 1665/4885 |
| US-10787460-B2 | (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7 | CDK7, CDK9, CDK8 | ALDH1A1 2171/4885HPGD 3112/4885SMN1; SMN2 1665/4885 |
| US-20210032257-A1 | (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7 | CDK7, CDK9, CDK8 | ALDH1A1 2171/4885HPGD 3112/4885SMN1; SMN2 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.